Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Devonian Health GroupDVHGF -0.17%35 Equity-to-Asset is 0.81 as of Apr. 2026, which is 35% above its 10-year median of 0.60. GuruFocus rates DVHGF with a GF Score™ of 35/100. The stock has 7 warning signs investors should review. Among 1,414 Biotechnology companies, Devonian Health Group ranks better than 67.54% on this metric.
Devonian Health Group (OTCPK:DVHGF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Devonian Health Group Equity-to-Asset Related Terms
Devonian Health Group Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Devonian Health Group's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DVHGF vs VRTX, REGN, MRNA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Devonian Health Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devonian Health Group Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Devonian Health Group's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Devonian Health Group's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Devonian Health Group's Equity to Asset Ratio for the fiscal year that ended in Jul. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Devonian Health Group (DVHGF) has a Equity-to-Asset of 0.81 as of Apr. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Devonian Health Group and its competitors. This is 35% above median its historical median of 0.60. Over the past decade, Devonian Health Group's Equity-to-Asset has ranged from 0.01 to 0.83. According to the industry distribution chart, Devonian Health Group ranks #459 out of 1414 companies in the Biotechnology industry, placing it in the top 32.5%.
Is Devonian Health Group's Equity-to-Asset too high?
Devonian Health Group's current Equity-to-Asset of 0.81 is 35% above median its 10-year median of 0.60. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.83. The Biotechnology industry median Equity-to-Asset is 0.68. Devonian Health Group's value of 0.81 is 19.1% above this industry median. Based on the distribution chart, Devonian Health Group ranks #459 out of 1414 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Devonian Health Group has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Devonian Health Group ranks #459 out of 1414 companies for Equity-to-Asset. This puts Devonian Health Group in the upper half of its industry. The industry median Equity-to-Asset is 0.68. Devonian Health Group's value of 0.81 is 19.1% above this benchmark. Historically, Devonian Health Group's own Equity-to-Asset has ranged from 0.01 to 0.83 over the past decade. While the company's 10-year median is 0.60 vs. the industry median of 0.68, Devonian Health Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Devonian Health Group's current Equity-to-Asset of 0.81 is 19.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Devonian Health Group and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Devonian Health Group's current Equity-to-Asset is 0.81, which is 35% above median its own 10-year median of 0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Devonian Health Group (DVHGF) has a current Equity-to-Asset of 0.81. The current Equity-to-Asset is 0.81, which is 35% above median its 10-year median of 0.60 and 19.1% above the Biotechnology industry median of 0.68. Devonian Health Group's overall GF Score™ is 35/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Devonian Health Group (DVHGF), the current Equity-to-Asset is 0.81 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
35GF Score
Get the complete analysis for DVHGF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DVHGF has been successfully added to your 
